Zhejiang Cancer Hospital
🇨🇳China
Akeso's Gumokimab (IL-17 mAb) Application Accepted for Psoriasis Treatment in China
• Akeso's gumokimab, an IL-17 targeting monoclonal antibody, has its NDA accepted by China's NMPA for treating moderate to severe plaque psoriasis.
• Clinical trials showed gumokimab's rapid efficacy, with PASI 75 response rates approaching 96% at week 12 and sustained improvement over 52 weeks.
• Safety profiles of gumokimab were comparable to placebo, indicating good tolerability, which addresses the need for safer psoriasis treatments.
• Akeso aims to meet diverse patient needs by combining gumokimab with other drugs like ebronucimab, enhancing their autoimmune disease product synergy.
Henlius to Present Latest Clinical Data of HLX10 and HLX22 at 2025 ASCO GI
Shanghai Henlius Biotech, Inc. will showcase the latest clinical data of its anti-PD-1 monoclonal antibody HANSIZHUANG (serplulimab) and innovative anti-HER2 monoclonal antibody HLX22 at the 2025 ASCO Gastrointestinal Cancers Symposium. The presentations will cover updated efficacy and safety profiles of these treatments in various gastrointestinal and lung cancer indications.
Phase 2b Trial of Glecirasib in KRAS G12C-Mutated Non-Small-Cell Lung Cancer
A phase 2b trial investigates the efficacy of Glecirasib in treating KRAS G12C-mutated non-small-cell lung cancer, involving multiple institutions across China and the USA.
Sacituzumab Govitecan Demonstrates Efficacy in HR+/HER2- Metastatic Breast Cancer
• Sacituzumab govitecan (SG) significantly improved progression-free survival (PFS) compared to chemotherapy in patients with HR+/HER2- metastatic breast cancer.
• The phase 3 EVER-132-002 trial included patients who had received two to four prior chemotherapy regimens, showing SG's benefit in heavily pre-treated populations.
• SG demonstrated a manageable safety profile, supporting its potential as a valuable treatment option for this patient population in regions including mainland China, Republic of Korea and Taiwan.
• The study's findings contribute to addressing the unmet need for effective therapies in HR+/HER2- metastatic breast cancer, particularly after multiple lines of treatment.
Ivonescimab Shows Promise in Combination Therapies for CRC, TNBC, and HNSCC
• Ivonescimab, a bispecific antibody, demonstrates encouraging anti-tumor activity and a manageable safety profile in Phase II trials for metastatic colorectal cancer (CRC).
• In advanced triple-negative breast cancer (TNBC), ivonescimab combined with chemotherapy achieved a 72.4% overall response rate and 100% disease control rate in first-line treatment.
• Ivonescimab, with or without ligufalimab, shows clinical benefit in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), with overall response rates of 30% and 60%, respectively.
• Summit Therapeutics plans to expand clinical development of ivonescimab in solid tumors beyond non-small cell lung cancer, based on positive Phase II data.
CD47-Targeted Immunotherapies Show Promise in Cancer Treatment
• CD47-targeted therapies are emerging as a novel cancer immunotherapy approach, inhibiting the "don't eat me" signal that cancer cells use to evade immune surveillance.
• Several CD47 inhibitors, like magrolimab and evorpacept, are undergoing clinical trials, showing encouraging results in hematological and solid tumors, often in combination with other treatments.
• Regulatory bodies are supportive, granting fast track designations and IND clearances, indicating a rapidly expanding CD47 market driven by the rising incidence of cancer.
• Pharmaceutical companies and research institutions are actively involved, with the United States leading the sector, while countries like China are increasing their engagement in clinical studies.
Ivonescimab and IBI363 Show Promise in Advanced Solid Tumors at ESMO 2024
• Ivonescimab demonstrates encouraging Phase II data in advanced triple-negative breast cancer, recurrent/metastatic head and neck squamous cell carcinoma, and metastatic microsatellite-stable colorectal cancer.
• IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein combined with bevacizumab, shows promising anti-tumor activity in advanced colorectal cancer.
• Updated Phase 3 MARIPOSA study results reveal significant overall survival improvement with amivantamab plus lazertinib over osimertinib in EGFR-mutant advanced NSCLC.
• Sacituzumab govitecan and ifinatamab deruxtecan demonstrate activity in extensive-stage small cell lung cancer, offering potential new treatment options.
© Copyright 2025. All Rights Reserved by MedPath